Cayuela, Jean-Michel <br/><br/>
[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].  [electronic resource] 

 -  Bulletin du cancer  Jan 2020 
 - 113-128 p.  digital 
<br/><br/> Publication Type: Consensus Development Conference; Journal Article; Practice Guideline; Review 
<br/><br/><label>ISSN: </label>1769-6917 
<br/><br/><label>Standard No.: </label>10.1016/j.bulcan.2019.05.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Catalytic Domain<br/>Clinical Decision-Making<br/>DNA Mutational Analysis--methods<br/>DNA, Neoplasm--analysis<br/>Drug Resistance, Neoplasm--genetics<br/>Drug Substitution<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Molecular Biology<br/>Mutation, Missense<br/>Point Mutation<br/>Protein Domains<br/>Protein Kinase Inhibitors--therapeutic use<br/>Role